NCT06420830
Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry With Central Echocardiography Analysis.
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Oct 1, 2026 to Oct 1, 2027
- Eligibility criteria shortened, about 2 words
- Publications: details revised at 7 of 7 entries
- Notable Primary completion date: Sep 1, 2025 to Oct 1, 2026
- Site contact updated
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary completion date: Sep 1, 2024 to Sep 1, 2025
- Start date changed from estimate of Jun 1, 2024 to May 16, 2024
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Transvalvular gradient
Timeframe: 1-3 months
Effective orifice area (EOA)
Timeframe: 1-3 months
Prosthesis-patient mismatch
Timeframe: 1-3 months
Paravalvular leaks
Timeframe: 1-3 months
Secondary (8)
Transvalvular gradient
Effective orifice area (EOA)
Bioprosthetic valve dysfunction
Paravalvular leaks
Bioprosthetic valve failure
Show 3 moreShow less
Clinical events
Valve thrombosis
Valve endocarditis
Arms and interventions
Procedures: SAPIEN 3 Ultra RESILIA Valve
Sites
1 site in 1 country
- IUCPQQuébec, Quebec, Canada